MiRXES

MiRXES is an RNA-technology diagnostics company founded in 2014 as a spin-off from the A*STAR Bioprocessing Technology Institute, headquartered in Singapore. Alongside its early cancer-detection tests, the company develops molecular diagnostic kits for infectious disease detection.

Its infectious disease line includes the Fortitude Kit 2.1 and the Fortitude SARS-CoV-2 and Flu A/B test, built on RNA extraction and RT-PCR technology. In 2020 the company mass-produced Singapore’s first approved COVID-19 PCR test kit and deployed it to about 35 countries. Manufacturing takes place in ISO13485-certified facilities in Singapore and Hangzhou, and MiRXES listed on the Hong Kong Stock Exchange in 2025.

1. RT-PCR Infectious Disease Kits: The Fortitude Kit 2.1 and the SARS-CoV-2 and Flu A/B test detect respiratory pathogens from patient samples.

2. Pandemic-Scale Manufacturing: The company mass-produced Singapore's first approved COVID-19 PCR test and shipped it to about 35 countries in 2020.

3. RNA Extraction Kits: MiRXES also supplies standalone RNA extraction reagents used in diagnostic workflows.

4. Certified Manufacturing: Production facilities in Singapore and Hangzhou hold ISO13485 certification.

5. Regional Distribution: Products reach Southeast Asia through the M Diagnostics network alongside direct operations in China, Japan, and the United States.

6. Public Listing: MiRXES listed on the Hong Kong Stock Exchange in 2025, raising HKD 1.09 billion.